<u date-time="vWcgh"></u><sub date-time="XeMd8"></sub><sub date-time="qmAIU4"><small dropzone="bkzheMB"></small></sub> "V体育官网入口" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Review
. 2015 Aug 12:7:253-64.
doi: 10.2147/CMAR.S58285. eCollection 2015.

"VSports" Progress toward overcoming hypoxia-induced resistance to solid tumor therapy

Sergey V Karakashev  1 , Mauricio J Reginato  1
Affiliations
Review

Progress toward overcoming hypoxia-induced resistance to solid tumor therapy

Sergey V Karakashev et al. Cancer Manag Res. .

Abstract

Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy VSports手机版. Hypoxia inducible factor 1, a major regulator of cellular response to hypoxia, regulates the expression of genes that are involved in multiple aspects of cancer biology, including cell survival, proliferation, metabolism, invasion, and angiogenesis. Here, we review multiple pathways regulated by hypoxia/hypoxia inducible factor 1 in cancer cells and discuss the latest advancements in overcoming hypoxia-mediated tumor resistance. .

Keywords: HIF-1; apoptosis; cancer; chemoresistance; signaling. V体育安卓版.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hypoxia/Hypoxia inducible factor 1 (HIF-1)-mediated mechanisms leading to anticancer therapy resistance. Notes: Under hypoxic conditions HIF-1 is stabilized, translocates to the nucleus, and activates expression of its target genes. Activity of many of these genes promotes resistance to anticancer therapy through regulation of metabolism, survival, drug efflux, signaling, and DNA repair.
Figure 2
Figure 2
Potential strategies to target hypoxic cancer cells in solid tumors. Notes: Multiple pathways may be targeted to reverse hypoxia-mediated anticancer therapy resistance. (1) Hypoxia inducible factor 1 (HIF-1) plays a critical role in cellular adaptation to hypoxic environment. Several agents can impair HIF-1 function by inhibiting its expression, translation, or transcriptional activity, or by promoting HIF-1 degradation. (2) Hypoxia-mediated angiogenesis plays an important role in tumorigenesis and could be targeted by anti-vascular endothelial growth factor (VEGF) therapy. (3) Multiple metabolic pathways are activated under hypoxia and the inhibition of these pathways targets hypoxic cells. (4) Activation of cancer signaling under hypoxia promotes proliferation, survival, and invasion. Targeting hypoxia/HIF-1-mediated signaling pathways has been shown to be efficient at decreasing tumorigenesis in vitro and in vivo. (5) Hypoxia and HIF-1 can remodel the extracellular matrix (ECM) in cancer cells that can also contribute to altered signaling by adhesion receptors such as integrins. The targeting ECM-regulating enzymes in hypoxic tumors may be used to reverse hypoxia-mediated resistance to cancer therapy. Abbreviations: Akt, protein kinase B; DCA, dichloroacetate; EGFR, epidermal growth factor receptor; FAS, fatty acid synthase; HIF-1α/β, hypoxia inducible factor 1 alpha/beta; HRE, hypoxia response element; LDHA, lactate dehydrogenase A; LOXL2, lysyl oxidase-like protein 2; PDK3, pyruvate dehydrogenase kinase 3; PI3K, phosphoinositide 3-kinase; RTK, receptor tyrosine kinase; VEGF-A, vascular endothelial growth factor-A.
See this image and copyright information in PMC

References

    1. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med (Berl) 2007;85(12):1301–1307. - "V体育ios版" PubMed
    1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–239. - VSports注册入口 - PubMed
    1. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26(2):241–248. - PubMed
    1. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003;29(4):297–307. - PubMed
    1. Ellis LM, Hicklin DJ. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res. 2009;15(24):7471–7478. - PubMed

Publication types

"V体育安卓版" Grants and funding